Selumetinib success in Phase II Biliary Cancer trial
Selumetinib, from AstraZeneca, has shown promising results in people with advanced Biliary Cancer, according to a multi-institutional clinical trial led by cancer researchers at The Ohio State University.
Selumetinib, also known as AZD 6244 (ARRY-142886), blocks a protein called MEK, which cancer cells need to proliferate and survive.- see Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers Tanios Bekaii-Saab, Mitch A. Phelps, Xiaobai Li, Motoyasu Saji, Laura Goff, John Sae Wook Kauh, Bert H. O'Neil, Stephanie Balsom, Catherine Balint, Ryan Liersemann, Vasily V. Vasko, Mark Bloomston, William Marsh, L. Austin Doyle, Gilian Ellison, Michael Grever, Matthew D. Ringel, and Miguel A. Villalona-Calero JCO Apr 25, 2011:; published online on April 25, 2011; DOI:10.1200/JCO.2010.33.9473.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.